Plus Therapeutics Inc (NASDAQ:PSTV) shares traded 17.65% higher at $1.60 on Wall Street last session.
In accordance with the data, 4 analysts cover Plus Therapeutics Inc (NASDAQ:PSTV). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $32.00 and a low of $4.00, we find $17.00. Given the previous closing price of $1.36, this indicates a potential upside of 1150.0 percent. PSTV stock price is now 4.21% away from the 50-day moving average and -51.92% away from the 200-day moving average. The market capitalization of the company currently stands at $7.23M.
It has been rated a hold by 0 analysts and a buy by 4. Brokers who have rated the stock have averaged $17.50 as their price target over the next twelve months.
With the price target of $8, Ladenburg Thalmann recently initiated with Buy rating for Plus Therapeutics Inc (NASDAQ: PSTV).
In other news, Clowes Howard, Director bought 6,993 shares of the company’s stock on Sep 13. The stock was bought for $10,022 at an average price of $1.43. Upon completion of the transaction, the Director now directly owns 11,693 shares in the company, valued at $18708.8. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 11, Director Petersen Greg bought 20,000 shares of the business’s stock. A total of $34,062 was incurred on buying the stock at an average price of $1.70. This leaves the insider owning 24,166 shares of the company worth $38665.6. Insiders disposed of 1,500 shares of company stock worth roughly $2400.0 over the past 1 year. A total of 1.37% of the company’s stock is owned by insiders.
Plus Therapeutics Inc (NASDAQ: PSTV) opened at $1.4900 on Friday. During the past 12 months, Plus Therapeutics Inc has had a low of $0.97 and a high of $7.50. As of last week, the company has a debt-to-equity ratio of 1.75, a current ratio of 1.10, and a quick ratio of 1.10. The fifty day moving average price for PSTV is $1.5190 and a two-hundred day moving average price translates $3.3024 for the stock.
The latest earnings results from Plus Therapeutics Inc (NASDAQ: PSTV) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.59, beating analysts’ expectations of -$1.91 by 1.32. This compares to -$2.85 EPS in the same period last year. The net profit margin was -404.27% and return on equity was -216.23% for PSTV. The company reported revenue of $1.24 million for the quarter, compared to $73000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1598.63 percent. For the current quarter, analysts expect PSTV to generate $1.29M in revenue.
Plus Therapeutics Inc(PSTV) Company Profile
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
